BioPharmSignal logoBioPharmSignal

Biotech News

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

Seres Therapeutics (MCRB)Seres TherapeuticsCompany update

Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization

Related news

MCRBSeres Therapeutics2026-11-03 12:00 EST

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

MCRBSeres Therapeutics2026-04-20 11:00 EST

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

View all latest news

Seres Therapeutics

Live Biotherapeutic Platform Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science. SER-155 SER-155 is...

Recent company news

MCRBSeres Therapeutics2026-11-04 12:00 EST

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

MCRBSeres Therapeutics2026-11-03 12:00 EST

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

MCRBSeres Therapeutics2026-10-15 11:00 EST

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

MCRBSeres Therapeutics2026-09-08 22:00 EST

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MCRBSeres Therapeutics2026-09-01 11:00 EST

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
2.09 USD
Market cap
70.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States